

# GEORGIAN MEDICAL NEWS

---

ISSN 1512-0112

NO 11 (344) ноябрь 2023

---

ТБИЛИСИ - NEW YORK



ЕЖЕМЕСЯЧНЫЙ НАУЧНЫЙ ЖУРНАЛ

Медицинские новости Грузии  
საქართველოს სამედიცინო სიახლენი

## GEORGIAN MEDICAL NEWS

Monthly Georgia-US joint scientific journal published both in electronic and paper formats of the Agency of Medical Information of the Georgian Association of Business Press.  
Published since 1994. Distributed in NIS, EU and USA.

**GMN: Georgian Medical News** is peer-reviewed, published monthly journal committed to promoting the science and art of medicine and the betterment of public health, published by the GMN Editorial Board since 1994. GMN carries original scientific articles on medicine, biology and pharmacy, which are of experimental, theoretical and practical character; publishes original research, reviews, commentaries, editorials, essays, medical news, and correspondence in English and Russian.

GMN is indexed in MEDLINE, SCOPUS, PubMed and VINITI Russian Academy of Sciences. The full text content is available through EBSCO databases.

**GMN: Медицинские новости Грузии** - ежемесячный рецензируемый научный журнал, издаётся Редакционной коллегией с 1994 года на русском и английском языках в целях поддержки медицинской науки и улучшения здравоохранения. В журнале публикуются оригинальные научные статьи в области медицины, биологии и фармации, статьи обзорного характера, научные сообщения, новости медицины и здравоохранения. Журнал индексируется в MEDLINE, отражён в базе данных SCOPUS, PubMed и ВИНТИ РАН. Полнотекстовые статьи журнала доступны через БД EBSCO.

**GMN: Georgian Medical News** – საქართველოს სამედიცინო სიახლენი – არის ყოველთვიური სამეცნიერო სამედიცინო რეცენზირებადი ჟურნალი, გამოიცემა 1994 წლიდან, წარმოადგენს სარედაქციო კოლეგიისა და აშშ-ის მეცნიერების, განათლების, ინდუსტრიის, ხელოვნებისა და ბუნებისმეტყველების საერთაშორისო აკადემიის ერთობლივ გამოცემას. GMN-ში რუსულ და ინგლისურ ენებზე ქვეყნდება ექსპერიმენტული, თეორიული და პრაქტიკული ხასიათის ორიგინალური სამეცნიერო სტატიები მედიცინის, ბიოლოგიისა და ფარმაციის სფეროში, მიმოხილვითი ხასიათის სტატიები.

ჟურნალი ინდექსირებულია MEDLINE-ის საერთაშორისო სისტემაში, ასახულია SCOPUS-ის, PubMed-ის და ВИНТИ РАН-ის მონაცემთა ბაზებში. სტატიების სრული ტექსტი ხელმისაწვდომია EBSCO-ს მონაცემთა ბაზებიდან.

### WEBSITE

[www.geomednews.com](http://www.geomednews.com)

## К СВЕДЕНИЮ АВТОРОВ!

При направлении статьи в редакцию необходимо соблюдать следующие правила:

1. Статья должна быть представлена в двух экземплярах, на русском или английском языках, напечатанная через **полтора интервала на одной стороне стандартного листа с шириной левого поля в три сантиметра**. Используемый компьютерный шрифт для текста на русском и английском языках - **Times New Roman (Кириллица)**, для текста на грузинском языке следует использовать **AcadNusx**. Размер шрифта - **12**. К рукописи, напечатанной на компьютере, должен быть приложен CD со статьей.

2. Размер статьи должен быть не менее десяти и не более двадцати страниц машинописи, включая указатель литературы и резюме на английском, русском и грузинском языках.

3. В статье должны быть освещены актуальность данного материала, методы и результаты исследования и их обсуждение.

При представлении в печать научных экспериментальных работ авторы должны указывать вид и количество экспериментальных животных, применявшиеся методы обезболивания и усыпления (в ходе острых опытов).

4. К статье должны быть приложены краткое (на полстраницы) резюме на английском, русском и грузинском языках (включающее следующие разделы: цель исследования, материал и методы, результаты и заключение) и список ключевых слов (key words).

5. Таблицы необходимо представлять в печатной форме. Фотокопии не принимаются. **Все цифровые, итоговые и процентные данные в таблицах должны соответствовать таковым в тексте статьи**. Таблицы и графики должны быть озаглавлены.

6. Фотографии должны быть контрастными, фотокопии с рентгенограмм - в позитивном изображении. Рисунки, чертежи и диаграммы следует озаглавить, пронумеровать и вставить в соответствующее место текста **в tiff формате**.

В подписях к микрофотографиям следует указывать степень увеличения через окуляр или объектив и метод окраски или импрегнации срезов.

7. Фамилии отечественных авторов приводятся в оригинальной транскрипции.

8. При оформлении и направлении статей в журнал МНГ просим авторов соблюдать правила, изложенные в «Единых требованиях к рукописям, представляемым в биомедицинские журналы», принятых Международным комитетом редакторов медицинских журналов - <http://www.spinesurgery.ru/files/publish.pdf> и [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html) В конце каждой оригинальной статьи приводится библиографический список. В список литературы включаются все материалы, на которые имеются ссылки в тексте. Список составляется в алфавитном порядке и нумеруется. Литературный источник приводится на языке оригинала. В списке литературы сначала приводятся работы, написанные знаками грузинского алфавита, затем кириллицей и латиницей. Ссылки на цитируемые работы в тексте статьи даются в квадратных скобках в виде номера, соответствующего номеру данной работы в списке литературы. Большинство цитированных источников должны быть за последние 5-7 лет.

9. Для получения права на публикацию статья должна иметь от руководителя работы или учреждения визу и сопроводительное отношение, написанные или напечатанные на бланке и заверенные подписью и печатью.

10. В конце статьи должны быть подписи всех авторов, полностью приведены их фамилии, имена и отчества, указаны служебный и домашний номера телефонов и адреса или иные координаты. Количество авторов (соавторов) не должно превышать пяти человек.

11. Редакция оставляет за собой право сокращать и исправлять статьи. Корректур авторам не высылаются, вся работа и сверка проводится по авторскому оригиналу.

12. Недопустимо направление в редакцию работ, представленных к печати в иных издательствах или опубликованных в других изданиях.

**При нарушении указанных правил статьи не рассматриваются.**

## REQUIREMENTS

Please note, materials submitted to the Editorial Office Staff are supposed to meet the following requirements:

1. Articles must be provided with a double copy, in English or Russian languages and typed or computer-printed on a single side of standard typing paper, with the left margin of 3 centimeters width, and 1.5 spacing between the lines, typeface - **Times New Roman (Cyrillic)**, print size - 12 (referring to Georgian and Russian materials). With computer-printed texts please enclose a CD carrying the same file titled with Latin symbols.

2. Size of the article, including index and resume in English, Russian and Georgian languages must be at least 10 pages and not exceed the limit of 20 pages of typed or computer-printed text.

3. Submitted material must include a coverage of a topical subject, research methods, results, and review.

Authors of the scientific-research works must indicate the number of experimental biological species drawn in, list the employed methods of anesthetization and soporific means used during acute tests.

4. Articles must have a short (half page) abstract in English, Russian and Georgian (including the following sections: aim of study, material and methods, results and conclusions) and a list of key words.

5. Tables must be presented in an original typed or computer-printed form, instead of a photocopied version. **Numbers, totals, percentile data on the tables must coincide with those in the texts of the articles.** Tables and graphs must be headed.

6. Photographs are required to be contrasted and must be submitted with doubles. Please number each photograph with a pencil on its back, indicate author's name, title of the article (short version), and mark out its top and bottom parts. Drawings must be accurate, drafts and diagrams drawn in Indian ink (or black ink). Photocopies of the X-ray photographs must be presented in a positive image in **tiff format**.

Accurately numbered subtitles for each illustration must be listed on a separate sheet of paper. In the subtitles for the microphotographs please indicate the ocular and objective lens magnification power, method of coloring or impregnation of the microscopic sections (preparations).

7. Please indicate last names, first and middle initials of the native authors, present names and initials of the foreign authors in the transcription of the original language, enclose in parenthesis corresponding number under which the author is listed in the reference materials.

8. Please follow guidance offered to authors by The International Committee of Medical Journal Editors guidance in its Uniform Requirements for Manuscripts Submitted to Biomedical Journals publication available online at: [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)  
[http://www.icmje.org/urm\\_full.pdf](http://www.icmje.org/urm_full.pdf)

In GMN style for each work cited in the text, a bibliographic reference is given, and this is located at the end of the article under the title "References". All references cited in the text must be listed. The list of references should be arranged alphabetically and then numbered. References are numbered in the text [numbers in square brackets] and in the reference list and numbers are repeated throughout the text as needed. The bibliographic description is given in the language of publication (citations in Georgian script are followed by Cyrillic and Latin).

9. To obtain the rights of publication articles must be accompanied by a visa from the project instructor or the establishment, where the work has been performed, and a reference letter, both written or typed on a special signed form, certified by a stamp or a seal.

10. Articles must be signed by all of the authors at the end, and they must be provided with a list of full names, office and home phone numbers and addresses or other non-office locations where the authors could be reached. The number of the authors (co-authors) must not exceed the limit of 5 people.

11. Editorial Staff reserves the rights to cut down in size and correct the articles. Proof-sheets are not sent out to the authors. The entire editorial and collation work is performed according to the author's original text.

12. Sending in the works that have already been assigned to the press by other Editorial Staffs or have been printed by other publishers is not permissible.

**Articles that Fail to Meet the Aforementioned  
Requirements are not Assigned to be Reviewed.**

## ავტორთა საქურაღებოლ!

რედაქციაში სტატიის წარმოდგენისას საჭიროა დაიცვათ შემდეგი წესები:

1. სტატია უნდა წარმოადგინოთ 2 ცალად, რუსულ ან ინგლისურ ენებზე დაბეჭდილი სტანდარტული ფურცლის 1 გვერდზე, 3 სმ სიგანის მარცხენა ველისა და სტრიქონებს შორის 1,5 ინტერვალის დაცვით. გამოყენებული კომპიუტერული შრიფტი რუსულ და ინგლისურენოვან ტექსტებში - **Times New Roman (Кириллица)**, ხოლო ქართულენოვან ტექსტში საჭიროა გამოვიყენოთ **AcadNusx**. შრიფტის ზომა – 12. სტატიას თან უნდა ახლდეს CD სტატიით.

2. სტატიის მოცულობა არ უნდა შეადგენდეს 10 გვერდზე ნაკლებს და 20 გვერდზე მეტს ლიტერატურის სიის და რეზიუმეების (ინგლისურ, რუსულ და ქართულ ენებზე) ჩათვლით.

3. სტატიაში საჭიროა გაშუქდეს: საკითხის აქტუალობა; კვლევის მიზანი; საკვლევი მასალა და გამოყენებული მეთოდები; მიღებული შედეგები და მათი განსჯა. ექსპერიმენტული ხასიათის სტატიების წარმოდგენისას ავტორებმა უნდა მიუთითონ საექსპერიმენტო ცხოველების სახეობა და რაოდენობა; გაუტკივარებისა და დაძინების მეთოდები (მწვავე ცდების პირობებში).

4. სტატიას თან უნდა ახლდეს რეზიუმე ინგლისურ, რუსულ და ქართულ ენებზე არანაკლებ ნახევარი გვერდის მოცულობისა (სათაურის, ავტორების, დაწესებულების მითითებით და უნდა შეიცავდეს შემდეგ განყოფილებებს: მიზანი, მასალა და მეთოდები, შედეგები და დასკვნები; ტექსტუალური ნაწილი არ უნდა იყოს 15 სტრიქონზე ნაკლები) და საკვანძო სიტყვების ჩამონათვალი (key words).

5. ცხრილები საჭიროა წარმოადგინოთ ნაბეჭდი სახით. ყველა ციფრული, შემაჯამებელი და პროცენტული მონაცემები უნდა შეესაბამებოდეს ტექსტში მოყვანილს.

6. ფოტოსურათები უნდა იყოს კონტრასტული; სურათები, ნახაზები, დიაგრამები - დასათაურებული, დანომრილი და სათანადო ადგილას ჩასმული. რენტგენოგრაფიების ფოტოასლები წარმოადგინეთ პოზიტიური გამოსახულებით **tiff** ფორმატში. მიკროფოტოსურათების წარწერებში საჭიროა მიუთითოთ ოკულარის ან ობიექტივის საშუალებით გადიდების ხარისხი, ანათალების შედეგების ან იმპრეგნაციის მეთოდი და აღნიშნოთ სურათის ზედა და ქვედა ნაწილები.

7. სამამულო ავტორების გვარები სტატიაში აღინიშნება ინიციალების თანდართვით, უცხოურისა – უცხოური ტრანსკრიპციით.

8. სტატიას თან უნდა ახლდეს ავტორის მიერ გამოყენებული სამამულო და უცხოური შრომების ბიბლიოგრაფიული სია (ბოლო 5-8 წლის სიღრმით). ანბანური წყობით წარმოდგენილ ბიბლიოგრაფიულ სიაში მიუთითეთ ჯერ სამამულო, შემდეგ უცხოელი ავტორები (გვარი, ინიციალები, სტატიის სათაური, ჟურნალის დასახელება, გამოცემის ადგილი, წელი, ჟურნალის №, პირველი და ბოლო გვერდები). მონოგრაფიის შემთხვევაში მიუთითეთ გამოცემის წელი, ადგილი და გვერდების საერთო რაოდენობა. ტექსტში კვადრატულ ფხიხლებში უნდა მიუთითოთ ავტორის შესაბამისი N ლიტერატურის სიის მიხედვით. მიზანშეწონილია, რომ ციტირებული წყაროების უმეტესი ნაწილი იყოს 5-6 წლის სიღრმის.

9. სტატიას თან უნდა ახლდეს: ა) დაწესებულების ან სამეცნიერო ხელმძღვანელის წარდგინება, დამოწმებული ხელმოწერითა და ბეჭდით; ბ) დარგის სპეციალისტის დამოწმებული რეცენზია, რომელშიც მითითებული იქნება საკითხის აქტუალობა, მასალის საკმაობა, მეთოდის სანდოობა, შედეგების სამეცნიერო-პრაქტიკული მნიშვნელობა.

10. სტატიის ბოლოს საჭიროა ყველა ავტორის ხელმოწერა, რომელთა რაოდენობა არ უნდა აღემატებოდეს 5-ს.

11. რედაქცია იტოვებს უფლებას შეასწოროს სტატია. ტექსტზე მუშაობა და შეჯერება ხდება საავტორო ორიგინალის მიხედვით.

12. დაუშვებელია რედაქციაში ისეთი სტატიის წარდგენა, რომელიც დასაბეჭდად წარდგენილი იყო სხვა რედაქციაში ან გამოქვეყნებული იყო სხვა გამოცემებში.

აღნიშნული წესების დარღვევის შემთხვევაში სტატიები არ განიხილება.

Stepanyan Lusine, Papoyan Varduhi, Galstyan Alina, Sargsyan Diana. THE PROBLEM OF COMPETENCIES MODELING IN THE SOCIAL-PSYCHOLOGICAL CRISIS CONDITIONS.....	6-12
Biduchak A, Mararash H, Mohammad Wathek O Alsalama, Chornenka Zh, Yasinska E. ORGANIZATIONAL AND FUNCTIONAL MODEL OF IMPROVEMENT OF THE SYSTEM OF PREVENTION OF CONFLICT SITUATIONS IN THE FIELD OF HEALTHCARE.....	13-18
Shalabh Kumar, Sanjay Kumar Yadav, Komal Patel, Renuka Jyothi. R, Bhupendra Kumar, Vikram Patidar. EARLY IMPLANT OUTCOMES IN ADULTS WITH DENTAL DECAY TREATED WITH PHOTODYNAMIC TREATMENT.....	19-26
M. Zubiashvili, N. Kakauridze, P. Machavariani, T. Zubiashvili. THE SIGNIFICANCE OF CIRCULATING SURFACTANT PROTEIN D(SP-D) AND DYSLIPIDEMIA IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CORONARY HEART DISEASE (CHD) AND THEIR COMBINATION.....	27-33
Mohamed Hamdi Mohamed Elgawadi, Yasser Abdel Fattah Radwan, Sherif Abdel Latif Othman, Ahmed Samir Barakat, Ahmed Omar Sabry, Abdallu Mohamed Ahmed. RANDOMIZED COMPARATIVE STUDY OF DEFINITIVE EXTERNAL FIXATION VERSUS ORIF IN PILON FRACTURES: AN EARLY CLINICAL OUTCOME REPORT.....	34-38
Salome Glonti, Megi Inaishvili, Irina Nakashidze. EVALUATION OF SOME LABORATORY PARAMETERS IN PATIENTS WITH MORBID OBESITY AFTER BARIATRIC SURGERY.....	39-42
Balbeer Singh, Soubhagya Mishra, Rajnish Kumar, Devanshu J. Patel, Malathi.H, Bhupendra Kumar. IMPLICATION OF THREAT FACTORS AND PREEEXISTING DISORDERS IN DIFFERENT ISCHEMIC STROKE SUBGROUPS IN ELDERLY PEOPLE: A SYSTEMATIC STUDY.....	43-46
Liubov Bilyk, Neonila Korylchuk, Dmytro Maltsev, Mykola Rudenko, Olena Kozeratska. TRANSFORMATION OF UKRAINIAN HEALTHCARE TO THE NEW CONDITIONS OF DEVELOPMENT: RISKS, SOLUTIONS, MODERNISATIONOPTIONS.....	47-52
Kozak N.P, Stakhova A.P. A CASE REPORT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS.....	53-56
Amandeep Singh, Pravesh Kumar Sharma, Ashok Kumar Singh, Chhaya Agarwal, Geetika M. Patel, Kavina Ganapathy. RELEVANCE FOR DIAGNOSIS, THERAPY, AND STRATEGIES OF GUT MICROBES DYSBIOSIS IN CHRONIC KIDNEY DISEASE: A SYSTEMATICREVIEW.....	57-63
Sharadze D. Z, Abramov A. Yu, Konovalov O.E, Fomina A.V, Generalova Yu.A, Kakabadze E. M, Bokova E. A, Shegai A.V, Kozlova Z.V, Fokina S.A. MEDICAL AND SOCIAL ASPECTS OF PREVENTING SPORTS INJURIES AMONG CHILDREN AND ADOLESCENTS.....	64-71
Hisham A. Ahmed, Abdulhameed N. Aldabagh, Abdulsattar S. Mahmood. COMPARISON BETWEEN PRE- AND POST-OPERATIVELY BOTOX INJECTION IN SECONDARY WOUNDS HEALING.....	72-76
Pantus A.V, Rozhko M.M, Paliychuk I.V, Kutsyk R.V, Kovalchuk N.Y. EFFECTIVENESS OF THE APPLICATION OF THE DEVELOPED BIOPOLYMER FIBROUS MATRIX WITH CENOBONE® BIOGEL FOR THE RECONSTRUCTION OF BONE TISSUE DEFECTS OF THE JAWS.....	77-84
Sherif W. Mansour, Nesrin R. Mwafi, Nafe' M. AL-Tawarah, Bayan Masoud, Hamzah A. Abu-Tapanjeh, Ibraheem M. Alkhalwaldeh, Mohammad S. Qawaqzeh, Raghad Amro, Sulieman B. Mazahreh. PREVALENCE OF LEFT/RIGHT CONFUSION AMONG MEDICAL STUDENTS IN MUTAH UNIVERSITY- JORDAN.....	85-89
Sadhanandham S, Preetam K, Sriram V, B Vinod Kumar, Pulkit M, TR Muralidharan. SEVERITY OF MITRAL REGURGITATION AND ITS ASSOCIATION WITH LEFT VENTRICULAR DYSFUNCTION AND BRAIN- NATRIURETIC PEPTIDE LEVELS IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE.....	90-93
Ahmed J. Ibrahim, Niam Riyadh. EVALUATION OF MIDPALATAL SUTURE MATURATION IN THREE AGE GROUPS IN 10-25 YEARS USING CONE-BEAM COMPUTEDTOMOGRAPHY.....	94-100
Mohammed J. Mohammed, Entedhar R. Sarhat, Mossa M. Marbut. HEPCIDIN AND IRON BIOMARKERS MODULATED IN HEMODIALYSIS PATIENTS.....	101-105
Hussein A. Ibrahim, Ammar L. Hussein. ESTIMATION OF VON WILLEBRAND FACTOR IN PATIENTS CARDIAC DISEASES.....	106-110
Mohammed L. Abdulateef, Nihad N. Hilal, Mohammed M. Abdul-Aziz. EVALUATION OF VITAMIN D SERUM LEVELS AND THYROID FUNCTION TEST IN HYPOTHYROIDISM IRAQI PATIENTS.....	111-113

Mohammed N. Mahmmod, Entedhar R. Sarhat. HEPCIDIN AND FERRITIN MODULATED IN OBESE MALE.....	114-118
Nato Gorgadze, Manana Giorgobiani, Jumber Ungiadze, Vera Baziari, Leila Axvlediani. EFFECTS OF MATERNAL BLOOD LEAD IN THE PRENATAL PERIOD ON NEWBORNS AND THE SPECIFICS OF THE CONDITION AT BIRTH.....	119-123
Harith S. Aziz, Ammar L. Hussein, Mohamed G. Zakari. MYELOPEROXIDASE AND COENZYME Q10 MODULATED IN THE CHRONIC KIDNEY DISEASE PATIENTS.....	124-128
Arnab Sain, Shilpi Awasthi, Oluwafunmilola UKOH (Adeyemi), Kanishka Wattage, Ahmed Elkilany, Adhish Avasthi. SAFE USE OF FLUOROSCOPY AND PERSONAL PROTECTION EQUIPMENT IN TRAUMA & ORTHOAEDICS.....	129-132
Azzam A. Ahmed. SUTURED VERSUS SUTURELESS CONJUNCTIVAL AUTOGRAFT FOR PRIMARY PTERYGIUM.....	133-136
Osmolian V, Avsievich Al, Parandiy Va, Okhman Ol, Loginova N. FORENSIC AND LEGAL SIGNIFICANCE OF HYPNOSIS DURING A CRIMINAL INVESTIGATION.....	137-146
Loqman J. Tawfiq, Ali K. Durib, Esraa S. Jameel. CONCENTRATION OF MALONDIALDEHYDE IN WIVES INFECTED WITH TOXOPLASMA GONDII WHICH CORRELATES WITH INTRAUTERINE INSEMINATION IN BAGHDAD'S POPULATION COUPLES.....	147-151
Georgi Tchernev, Naydekova N. MELANOMA AND DYSPLASTIC NEVI DEVELOPMENT AFTER RANITIDINE/RILMENIDINE/MOXONIDINE, LERCANIDIPINE, ROSUVASTATIN AND VERAPAMIL/TRANDOLAPRIL- NEW DATA/CASE SERIES. THE POTENTIAL ROLE OF NITROSAMINE/ NDSRIS CONTAMINATION IN POLYMEDICATION AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.....	152-158
Qutaiba A. Qasim. HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) SYNDROME AMONG HEMODIALYSIS PATIENTS AND DISEASE MANAGEMENT STRATEGY.....	159-170
Oleg Batiuk, Iryna Hora, Valeriy Kolesnyk, Inna Popovich, Antonina Matsola. MEDICAL AND FORENSIC IDENTIFICATION OF PERSONS WHO HAVE BECOME VICTIMS OF WAR CRIMES OF THE RUSSIAN WAR AGAINST UKRAINE.....	171-179
F. Kh. Umarov, Ju.D. Urazbaev. PATIENT-RELATED FACTORS AFFECTING THE RISK OF COMPLICATIONS AFTER PRIMARY TOTAL HIP ARTHROPLASTY.....	180-186
Arnab Sain, Ahmed Elkilany, Arsany Metry, Marina Likos-Corbett, Emily Prendergast, Kanishka Wattage, Adhish Avasthi. OCCUPATIONAL HAZARDS IN ORTHOPAEDIC PROCEDURES-A NARRATIVE REVIEW OF CURRENT LITERATURE.....	187-190
Dhanya R.S, Pushpanjali K. IMPACT OF CULTURAL FACTORS ON THE DENTAL HEALTH STATUS AND BEHAVIOUR OF FEMALES IN THEIR GESTATION PERIOD.....	191-195
Georgi Tchernev. MULTIPLE KERATINOCYTIC CANCERS AFTER ENALAPRIL/LOSARTAN INTAKE: POTENTIAL LINKS TO DRUG MEDIATED NITROSOGENESIS/ CARCINOGENESIS: MELOLABIAL ADVANCED FLAP AND UNDERMINING SURGERY AS OPTIMAL THERAPEUTIC APPROACH.....	196-199
Subhrajee Chakraborty, Ankur Khandelwal, Rashmi Agarwalla, Limalemla Jamir, Himashree Bhattacharyya. ARTIFICIAL INTELLIGENCE: CREATING NEW PARADIGMS IN THE MANAGEMENT OF NON-COMMUNICABLE DISEASES.....	200-202
VILCAPOMA URETA LIZVE, AYALA GUEVARA KAREN JANET, JUNCHAYA YLLESCAS VILMA AMPARO, PARIJULCA FERNANDEZ ISRAEL ROBERT. COMPARISON OF THE EFFICACY OF TRAMADOL AND DICLOFENAC IN RELIEVING POSTOPERATIVE PAIN OF LAPAROSCOPIC CHOLECYSTECTOMY.....	203-206

## ARTIFICIAL INTELLIGENCE: CREATING NEW PARADIGMS IN THE MANAGEMENT OF NON-COMMUNICABLE DISEASES

Subhrajeet Chakraborty<sup>1</sup>, Ankur Khandelwal<sup>2</sup>, Rashmi Agarwalla<sup>3\*</sup>, Limalemla Jamir<sup>4</sup>, Himashree Bhattacharyya<sup>5</sup>.

<sup>1</sup>Senior Resident, Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India.

<sup>2</sup>Associate Professor, Department of Anaesthesiology, Critical Care and Pain Medicine, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India.

<sup>3</sup>Assistant Professor, Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India.

<sup>4</sup>Assistant Professor, Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India.

<sup>5</sup>Associate Professor, Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India.

### Abstract.

The role of Artificial Intelligence (AI) in medical science is growing immensely. Since AI contains features that can address both preventive and therapeutic aspects of non-communicable diseases (NCDs), it can potentially lessen the massive burden of morbidity and mortality associated with NCDs. AI can help in various ways in NCDs including predicting disease occurrence, monitoring, ensuring adherence to treatment and follow-up of patients. Low- and middle-income countries can harness the benefit of AI for the management of chronic diseases and effectively address challenges like manpower shortage, accessibility to health care, etc. However, AI needs to be used responsibly and rationally in NCDs for its maximum benefit.

**Key words.** Artificial intelligence, developing countries, morbidity, noncommunicable diseases.

### Introduction.

The world is now witnessing an epidemiological transition from communicable to non-communicable diseases (NCDs). The burden of NCDs is immense and accounts for 74% of all deaths globally. Cardiovascular diseases, stroke, cancers, chronic respiratory diseases, and diabetes account for most NCDs related deaths. Evidence shows that large number of NCDs related deaths are premature and occur before the age of 70. Approximately 86% of the premature deaths occur in low- and middle-income countries [1].

With a vast population either afflicted or at danger, the worldwide burden of NCDs is increasing, necessitating a digitalized approach to the analysis of the enormous data accessible from various sources for NCDs detection and management. With the fast growth of artificial intelligence (AI), there is great promise for improving patient treatment and outcomes through the analysis of data linked to NCDs and the creation of predictive models using AI. AI might play a significant role in monitoring of vital parameters, forecast key problems, aid in diagnosis and management and facilitating follow up of patients [2,3]. Additionally, the episodic treatment approach for NCDs that is now hospital-centric may be replaced with a more holistic, 24/7 continuum of care strategy with the use of AI. This may be accomplished with the use of technology like continuous monitoring by devices that can produce real-time data and inform medical professionals of any unforeseen issues that may develop in patients with NCDs. Numerous benefits of AI have been shown, including cost effectiveness, dependability, and data loss control [3].

Most NCD's are asymptomatic in the beginning, hence the diagnosis of these NCDs is delayed. The delay in diagnosis has implications on morbidity and mortality. In addition to human data, AI tools can collect data continuously from non-conventional sources such as social media, online search engines, forums, mobile applications, and other sources. These sources can offer more nuanced information about various socio-behavioural and other factors that may contribute to the onset or exacerbation of pre-existing NCDs [4].

### Current scenario.

While the scientific community debates the benefits and drawbacks of AI, it has already been included into NCDs treatment through a variety of methods. In this article, the authors have conducted a literature review on the application and difficulties of AI in the management of NCDs.

### Predicting disease occurrence

As is well known, the cause of NCDs is multifaceted and depends on a number of variables, including age, sex, ethnicity, familial characteristics, food, and addiction history. The aforementioned parameters have been used as predictors in several models that have been developed.

Villar et al. has developed a movement detection device for early stroke prediction. Two machine learning algorithms are incorporated in the device. The detection process includes a human activity recognition state and a stroke onset detection stage. If there is any noticeable change in the movement pattern as compared to the normal, immediately a stroke alert is issued, and the patient can be evaluated as early as possible [5].

Additionally, machine learning (ML) techniques have been used to analyse computed tomography (CT) scan data from stroke victims. After a stroke, free-floating intraluminal thrombus can develop as a lesion that is difficult to identify from carotid plaque on a CT scan. To categorize these two categories using quantitative form analysis, Thornhill et al. employed three ML methods, including linear discriminant analysis, artificial neural network, and support vector machine. Each method's accuracy ranges from 65.2% to 76.4% [6].

### Monitoring patients

Since the advent of wearable devices, it has become easier to have a continuous watch on certain parameters. Although wearable gadgets have not made a deep inroad into the markets of developing countries, AI based real time surveillance has become a potent tool in the management of NCDs across many



developed nations. We can consider the example of Sweden where remote sensor-based monitoring of patients is predicted to reduce annual health care expenditure by 3 billion Euros by 2025 [7]. Application of AI based technologies in remote monitoring of conditions such as arrhythmias are already in place in certain developed nations like USA [8].

AI based monitoring has been used to determine the risk of obesity by monitoring the meal timings and duration of the subjects through monitoring of hand movements and breathing pattern [9].

### **Ensuring medication adherence**

Medication adherence is defined as the extent to which a patient's behaviour regarding medication corresponds to the recommendations of their physician [10]. Medication adherence is one of the cornerstones in achieving control of NCDs such as diabetes and hypertension. Medication non-adherence has been linked to a wide array of negative outcomes such as hospital admissions and mortality [11]. Currently, there are mobile based services which are under use to ensure adherence to medications for tuberculosis in India. It has been proved by studies elsewhere in the world that monitoring patients through online apps can indeed improve adherence to medications [12].

Data from various countries have shown how AI can benefit prevention and treatment of NCDs. Many countries maintain online diabetes registry and it helps health professionals to keep track of the patients and tailor their needs. Similarly maintained databases are useful for diagnosis, treatment and prevention of cancers [13].

### **Possible avenues of AI in the management of NCDs in low- & middle-income nations.**

Although AI has been able to garner significant traction in high income countries, the workforce in low- and middle-income nations have lagged behind by some strides when it comes to implementation of newer AI based technologies.

#### **1. Data mining**

In the developing nations, the lack of actionable data has led to deadlock in the implementation of proper data driven research. Their consumer usage of smart devices will increase as these countries' economies develop, providing the necessary data for more study.

#### **2. Online surveillance**

While there may be a range of reactions to the term "online surveillance" from academics to the general public, AI based online surveillance can facilitate access to credible information to public by countering common myths and falsities that are commonly spread via social media networks. Also, it can help in creating a baseline database and monitoring the trend of NCDs, which is lacking in low- and middle-income countries.

#### **3. Patient empowerment**

AI can be used in the form of chatbots and other similar interactive technologies to disseminate information regarding NCDs and eliminate misconceptions and apprehensions about the same. Wefight Inc. designed a chatbot (Vik) utilizing Natural Language Processing Algorithms, in order to empower breast cancer patients and their relatives. It offered pertinent, well-researched medical details about breast cancer epidemiology,

therapies, and side effects, as well as details on fertility, lifestyle, medical reimbursements, patient rights, and other topics [14]. A study found that patients who regularly interacted with the chatbot were more compliant to the treatment protocols [15].

### **Challenges in implementation of AI based management of NCDs.**

AI has a broad role in health care systems for diagnosis, prediction of disease progression, and prevention purposes. However, there are several challenges that are posed towards proper implementation of AI in developing and underdeveloped nations. These can be broadly classified as following:

#### **Lack of trained workforce**

The developing and under-developed nations who are at biggest risk of NCDs related pre-matured mortalities are the ones who lack trained manpower to design proper AI tools customised for the local settings in order to tackle the problems of NCD management. In India, the total investment on AI during the period between 2013-2022 was USD 7.73 Billion. During the same period, USA and China invested 248.9 billion USD and 95.11 billion USD in their respective AI start-ups and programs [16].

#### **Social inequities**

While AI has the potential to be a very useful tool for promoting health equity in the long term, it also has the potential to reinforce already-existing disparities [17]. This inequity can be even more pronounced in the aspect of public health which encompasses NCD care at a mass level. The selection of the research topic, the representativeness of the data, the choice of the result definition, the optimization choices made during algorithm creation, and the post-deployment considerations can all lead to inequities [18,19].

#### **Difficult interpretation of AI algorithms**

AI technologies and their results can often be very difficult to interpret because of their complicated and non-linear modelling, which makes it difficult to grasp how the results were arrived at. This can lead to scepticism and lack of acceptance amongst both health care providers as well as beneficiaries [20]. Governments, who often take a risk-averse stance, make the final choices about the adoption of emerging technology. Verifying the veracity of data and compiling vast amounts of it is a monumental undertaking.

#### **Privacy Concerns**

This is perhaps one of the most asked questions in the current digital age. A significant portion of the data used to power AI technology comes from anonymised data sources, but there is always a chance that the anonymized replies might be re-identified, which could lead to the stigmatisation of minorities [21].

#### **Conclusion.**

Evidence suggests that AI approaches have been used to offer NCD services, and that they have a great deal of promise to reduce the burden of providing adherence to treatment and follow-up services for NCDs.

## REFERENCES

1. Non communicable diseases. 2023. <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>
2. Okeibunor JC, Jaca A, Iwu-Jaja CJ, et al. The use of artificial intelligence for delivery of essential health services across WHO regions: a scoping review. *Front Public Health.* 2023;11:1102185.
3. Tekkeşin Aİ. Artificial Intelligence in Healthcare: Past, Present and Future. *Anatol J Cardiol.* 2019;22:8-9.
4. Shaban-Nejad A, Michalowski M, Buckeridge DL. Health intelligence: how artificial intelligence transforms population and personalized health. *NPJ Digit Med.* 2018;1:53.
5. Villar JR, González S, Sedano J, et al. Improving human activity recognition and its application in early stroke diagnosis. *Int J Neural Syst.* 2015;25:1450036.
6. Thornhill RE, Lum C, Jaber A, et al. Can shape analysis differentiate free-floating internal carotid artery thrombus from atherosclerotic plaque in patients evaluated with CTA for stroke or transient ischemic attack? *Acad Radiol.* 2014;21:345-54.
7. Digitizing healthcare in Sweden | McKinsey. 2023. <https://www.mckinsey.com/industries/healthcare/our-insights/digitizing-healthcare-in-sweden>
8. Dubey A, Tiwari A. Artificial intelligence and remote patient monitoring in US healthcare market: a literature review. *J Mark Access Health Policy.* 2023;11:2205618.
9. Dong B, Biswas S. Meal-time and duration monitoring using wearable sensors. *Biomedical Signal Processing and Control.* 2017;32:97-109.
10. Babel A, Taneja R, Mondello Malvestiti F, et al. Artificial Intelligence Solutions to Increase Medication Adherence in Patients With Non-communicable Diseases. *Front Digit Health.* 2021;3:669869.
11. Mongkhon P, Ashcroft DM, Scholfield CN, et al. Hospital admissions associated with medication non-adherence: a systematic review of prospective observational studies. *BMJ Qual Saf.* 2018;27:902-914.
12. Labovitz DL, Shafner L, Reyes Gil M, et al. Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy. *Stroke.* 2017;48:1416-1419.
13. Mollura DJ, Culp MP, Pollack E, et al. Artificial Intelligence in Low- and Middle-Income Countries: Innovating Global Health Radiology. *Radiology.* 2020;297:513-20.
14. Chaix B, Guillemasse A, Nectoux P, et al. Vik: A Chatbot to Support Patients with Chronic Diseases. *Health.* 2020;12:804-810.
15. Chaix B, Bibault JE, Pienkowski A, et al. When Chatbots Meet Patients: One-Year Prospective Study of Conversations Between Patients With Breast Cancer and a Chatbot. *JMIR Cancer.* 2019;5:e12856.
16. AI Index Report 2023 – Artificial Intelligence Index. 2023. <https://aiindex.stanford.edu/report/>
17. Weiss D, Rydland HT, Øversveen E, et al. Innovative technologies and social inequalities in health: A scoping review of the literature. *PLoS One.* 2018;13:e0195447.
18. Smith MJ, Axler R, Bean S, et al. Four equity considerations for the use of artificial intelligence in public health. *Bull World Health Organ.* 2020;98:290-292.
19. Chen IY, Pierson E, Rose S, et al. Ethical Machine Learning in Healthcare. *Annu Rev Biomed Data Sci.* 2021;4:123-144.
20. Asan O, Bayrak AE, Choudhury A. Artificial Intelligence and Human Trust in Healthcare: Focus on Clinicians. *J Med Internet Res.* 2020;22:e15154.
21. Dolley S. Big Data's Role in Precision Public Health. *Front Public Health.* 2018;6:68.